Le Lézard
Classified in: Health
Subject: SVY

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028


NEW YORK, Jan. 24, 2020 /PRNewswire/ --

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

Summary

Read the full report: https://www.reportlinker.com/p05842037/?utm_source=PRN

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms.The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017).

Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

Epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast.The disease definition for COPD was based on symptoms and the results of spirometry testing.

The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. Epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope
- The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ?35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
- The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
- Understand magnitude of COPD population by severity at diagnosis.

Read the full report: https://www.reportlinker.com/p05842037/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 21:45
Biotech Institute, LLC, the global leader in hemp and cannabis plant breeding, science, and innovation, and Booshoot, LLC ("Booshoot") announced today that they have finalized a groundbreaking technology licensing agreement that will set a new...

at 21:00
UBM BN Co., Ltd., the fair manager of SECON 2020 originally scheduled for 18 - 20 March 2020 has made the decision to reschedule the event to 6 - 8 July at KINTEX, Korea.   The decision is taken after careful consideration and close consultations...

at 20:42
Nanalysis Scientific Corp. ("Nanalysis", TSXV:NSCI) is pleased to announce that it won the award for 'Best New Analytical Product' at the recent Nanotech Exhibition and Conference in Tokyo, Japan. Nanalysis was the only small-cap, non-Japanese...

at 20:22
Vanda Pharmaceuticals Inc. (Vanda) today announced it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Tuesday, February 25,...

at 20:05
Gilead Sciences, Inc. today announced that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the Cowen and Company 40th Annual Health Care Conference in Boston on...

at 20:00
ASIAWATER 2020 originally scheduled from March 31- April 1, 2020 has now moved to the revised dates of 30 November ? 2 December, 2020 at the Kuala Lumpur Convention Center (KLCC).  According to Informa Markets, the Organizer of ASIAWATER 2020, the...



News published on 24 january 2020 at 08:00 and distributed by: